« Previous Next » Urology
Volume 57, Issue 4, Supplement 1 , Pages 4-27 , April 2001

Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations

Ronald Lieberman
- National Cancer Institute, Rockville, Maryland, USA (RL)
- Reprint requests: Ronald Lieberman, MD, Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, 5130 Executive Blvd. EPN 2105, Rockville, MD 20852
William G Nelson
- Johns Hopkins University, Baltimore, Maryland, USA (WGN, AWP)
Wael A Sakr
- Wayne State University, Detroit, Michigan, USA (WS)
Frank L Meyskens Jr.
- University of California at Irvine, Irvine, California, USA (FLM)
Eric A Klein
- Cleveland Clinic Foundation, Cleveland, Ohio, USA (EAK)
George Wilding
- University of Wisconsin, Madison, Wisconsin, USA
Alan W Partin
- Johns Hopkins University, Baltimore, Maryland, USA (WGN, AWP)
J.Jack Lee
- University of Texas, Houston, Texas, USA (JJL, SML)
Scott M Lippman
- University of Texas, Houston, Texas, USA (JJL, SML)

References

Report of the Chemoprevention Implementation Group, National Cancer Institute, Bethesda, MD, September 10, 1999.
De Marzo AM, Putzi MJ, Nelson WG. New concepts in the pathology of prostatic epithelial carcinogenesis. Urology. 2001;57(suppl 4A):103–114
Trock BJ. Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials. Urology. 2001;57(suppl 4A):241–247
Lopaczynski W, Hruszkewycz AM, Lieberman R. Preprostatectomy (a clinical model to study stromal-epithelial interactions). Urology. 2001;57(suppl 4A):194–199
Weiss HL, Urban DA, Grizzle WE, et al. Bayesian monitoring of a phase II chemoprevention trial in high risk cohorts for prostate cancer. Urology. 2001;57(suppl 4A):220–223
Lee JJ, Lieberman R, Sloan JA, et al. Design considerations for efficient prostate cancer chemoprevention trials. Urology. 2001;57(suppl 4A):205–212
Gail MA, Brinton LA, Byar DP, et al: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 81: 1879–1886, 1989.
AACR Task Force on Intraepithelial Neoplasia. AACR Annual Meeting, San Francisco, CA, April 2000.
US Food and Drug Administration Oncology Division Advisory Committee (ODAC), Bethesda, MD, December 1999.
Lieberman R. Prostate cancer chemoprevention (strategies for designing efficient clinical trials). Urology. 2001;57(suppl 4A):224–229
Moul JW. Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials. Urology. 2001;57(suppl 4A):174–177